TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
← All Stock Lists
▌Top Stocks · TELEHEALTH·Updated November 2, 2026

Top Telehealth Stocks: Our 7 Picks for November 2026

A seven-stock countdown spans consumer telehealth, virtual-care platforms, physician enablement and chronic-care programs, with lower-ranked names including Teladoc, LifeMD and American Well.

Top Stocks · TELEHEALTHUpdated November 2, 2026
VSEEPRVAAMWLLFMDTDOC+2 locked
Last refreshed November 2, 2026·12 min read
Top Telehealth Stocks: Our 7 Picks for November 2026

Telehealth investing has entered a more demanding phase. The post-pandemic reset has pushed investors away from the idea that virtual care will simply replace brick-and-mortar medicine and toward companies with durable demand, visible reimbursement pathways and a credible route to operating leverage. That shift creates a wider gap between businesses that can embed digital care in ongoing clinical relationships and those still dependent on commoditized visit volume. The result is a theme with meaningful long-term potential, but one that requires more than identifying a company with a video-visit product.

The structural drivers remain substantial: aging populations, chronic-disease management, behavioral-health access, employer and payer cost pressure, and the convenience of digital-first care. The investable universe spans consumer telehealth and direct-to-patient platforms, payer- and employer-facing virtual care, enterprise and hospital infrastructure, and remote monitoring or chronic-care programs. Hybrid care is increasingly the norm, while bundled offerings that connect telehealth with pharmacy, diagnostics or longitudinal support may have a stronger economic foundation than standalone video visits.

This countdown covers seven U.S.-listed companies with different ways to participate in that transition. Teladoc Health’s launch of Teladoc One, a connected-care model for the U.S. market, illustrates the category’s movement toward integrated, multi-service care. The picks are presented in countdown order from #7 to #1, with the strongest combination of thematic exposure and business fundamentals reserved for the final selection.

Our screen focused on companies with a direct, meaningful connection to telehealth, virtual care, digital chronic-care management or the technology that enables those services. Rankings first reflect depth of exposure to the theme, then business fundamentals, including growth, profitability, valuation, earnings execution and balance-sheet considerations captured in our composite metrics. The universe constraint was U.S.-listed companies with market capitalization above $500 million. This is a countdown: the best pick is revealed at #1.

7. — VSee Health, Inc.

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

VSEE

Market cap: $1.5M · Quality grade: C · Analyst consensus: Sell (avg target $5.00)

What they do. The company provides telehealth solutions for acutely ill patients in neurointensive, cardiac intensive and other intensive-care settings. Its iDoc offering is supplemented by software building blocks for patient engagement, clinician staffing, remote physical examination, remote patient monitoring, AI-enabled telesitter and telenursing workflows, data connectors and workflow templates, sold through resellers, affiliated hospitals and sales executives.

Why it fits. VSee has unusually direct exposure to enterprise and hospital telehealth rather than a consumer-only virtual-care model. Its focus on stroke, spinal cord, brain trauma and other neurological conditions, along with remote monitoring and intensive-care coordination, aligns with the sector’s shift toward clinical workflows and hybrid care.

Numbers that matter. Revenue growth was 48% year over year, but revenue was only $15.8 million and EBITDA was negative $8.3 million. Gross margin was 43.4%, while operating margin was negative 172.7% and net margin was negative 62.6%, underscoring the distance to sustainable profitability. Trailing P/E was not available because the company remained loss-making, with trailing EPS of negative $42.51 and next-year EPS estimated at negative $0.36.

Recent momentum. VSee’s reported estimate history shows one beat in two quarters with available comparisons: a 75.0% beat on November 14, 2025, followed by a 300.0% miss on August 28, 2025. The analyst consensus is Sell with an average target of $5.00, while the composite quality grade is C and the overall recommendation is Sell.

6. PRVA — Privia Health Group Inc

Market cap: $2.7B · Quality grade: A- · Analyst consensus: Buy (avg target $31.47)

What they do. Privia is a physician-enablement company that works with physician practices, health plans and health systems. Its technology and population-health tools, management services organization, single-TIN medical group, accountable care organization and payer network support workflow efficiency, clinical integration, care coordination and value-based-care arrangements.

Why it fits. Privia is not a pure-play virtual-visit provider, but it offers exposure to the infrastructure around digitally enabled, coordinated care. Its population-health platform and accountable care organization connect providers, patients and payers, making it relevant to the employer- and payer-facing side of telehealth as hybrid care becomes embedded in broader medical delivery.

Numbers that matter. Revenue reached $2.36 billion and grew 21.4% year over year, while earnings growth was 250%. Profitability remains thin: gross margin was 10.0%, operating margin was 1.86% and net margin was 1.19%, with EBITDA of $56.9 million. Trailing P/E was 102.2857 and forward P/E was 19.4553, while EPS was $0.21 and next-year EPS was estimated at $1.063.

Recent momentum. The latest reported quarter, August 6, 2026, missed its $0.08 EPS estimate with actual EPS of $0.07, a 12.5% shortfall; the May quarter also missed by 24.0%. Earlier results were stronger, including a 75.0% beat in February 2026, and the seven-quarter record shows four beats. Analysts include five Buys and one Hold, producing a Buy consensus and $31.47 average target.

5. AMWL — American Well Corp

Market cap: $216.5M · Quality grade: B- · Analyst consensus: Hold (avg target $12.80)

What they do. American Well provides enterprise software and services for digitally enabled hybrid care in the U.S. and internationally. Its offerings include the Amwell Platform, Carepoint devices, Converge, behavioral-health and specialty-care programs, the Amwell Medical Group network, and implementation, workflow-design, integration and engagement services for providers, payers, government and higher education customers.

Why it fits. American Well has one of the clearest enterprise telehealth exposures in the group because its products are designed to connect virtual, automated and in-person care settings. Carepoint devices and Converge also give the company a role in hospital and clinical-site workflows, while specialty and behavioral-health programs extend beyond basic video consultations.

Numbers that matter. Revenue was $218.5 million but declined 26.6% year over year, and EBITDA was negative $39.9 million. Gross margin was 52.6%, yet operating margin was negative 19.59% and net margin was negative 35.75%; ROE and ROA were also negative 29.12% and negative 12.65%, respectively. Trailing and forward P/E were unavailable, with trailing EPS of negative $4.77 and next-year EPS estimated at negative $1.58.

Recent momentum. American Well beat EPS estimates in six of the seven reported quarters, including the August 4, 2026 quarter by 1.7% and the May quarter by 13.0%. However, the upcoming November 3 estimate remains negative at $0.66 per share. Six analysts are at Hold, with no Buy or Sell count reported, and the average target is $12.80.

Get AI research on any stock

Instant reports, daily intelligence, and an AI analyst in your pocket.

Get Started →

4. LFMD — LifeMD Inc

Market cap: $110.5M · Quality grade: D+ · Analyst consensus: Strong Sell (avg target $8.13)

What they do. LifeMD is a direct-to-patient telehealth company that combines virtual medical care with pharmacy services. Its Rex MD men's-health platform, ShapiroMD hair-loss business, LifeMD PC virtual primary-care service and offerings in chronic care, diagnostics, GLP-1 weight management and in-home monitoring give it a consumer-focused, multi-service revenue model.

Why it fits. LifeMD directly represents the consumer telehealth and direct-to-patient segment. Its combination of consultations, prescriptions, pharmacy services, diagnostics, wellness coaching and connected in-home tools fits the industry’s movement toward longitudinal and bundled care rather than isolated virtual visits.

Numbers that matter. Revenue was $191.6 million and declined 3.5% year over year, while EBITDA was negative $19.0 million. Gross margin was a strong 87.5%, but operating margin was negative 15.08%; net margin was only 0.11%. The forward P/E was 12.8535, but trailing EPS was negative $0.51 and the latest quote-based P/E was negative 4.58, so the forward valuation depends on a meaningful earnings improvement.

Recent momentum. LifeMD has beaten estimates in two of the seven reported quarters. The August 5, 2026 quarter beat by 20.0%, but the May quarter missed by 29.9%, and the November 9 estimate calls for negative $0.14 EPS. The analyst consensus field is 5, with an average target of $8.125 and no Buy, Hold or Sell count reported; the composite recommendation is Strong Sell.

3. TDOC — Teladoc Inc

Market cap: $1.6B · Quality grade: B- · Analyst consensus: Hold (avg target $8.15)

What they do. Teladoc provides virtual healthcare worldwide through its Integrated Care and BetterHelp segments. The company offers general, specialty and chronic-condition care, enterprise telehealth technology for hospitals and health systems, and online counseling and therapy through BetterHelp to employers, health plans, institutions and individual members.

Why it fits. Teladoc offers broad exposure across consumer mental health, employer and payer programs, chronic-condition management and hospital telehealth infrastructure. The launch of Teladoc One, its connected-care model for the U.S. market, is consistent with the sector’s move toward integrated services rather than standalone video visits.

Numbers that matter. Revenue was $2.47 billion but declined 3.4% year over year, while EBITDA was positive at $85.5 million. Gross margin was 68.6%, but operating margin was negative 3.66% and net margin was negative 6.27%; ROE was negative 11.52% and ROA was negative 2.93%. Forward P/E was 303.0303, alongside trailing EPS of negative $0.86 and next-year EPS estimated at negative $0.5967.

Recent momentum. Teladoc beat EPS estimates in all eight reported quarters. On October 28, 2026, it reported negative $0.15 versus an estimate of negative $0.23, a 34.8% beat; the July quarter beat by 12.5%. Analysts include one Buy and 17 Holds, producing a Hold consensus and an average target of $8.1471, while the composite recommendation remains Sell.

Pick #2Premium members only

Premium members see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →
Pick #1Premium members only

Premium members see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Methodology

This monthly screen evaluates U.S.-listed companies with market capitalization above $500 million and a meaningful connection to telehealth, virtual care, remote monitoring, digital chronic-care management or enabling infrastructure. The ranking is based first on depth of exposure to the telehealth theme and then on business fundamentals, including revenue and earnings growth, margins, valuation, earnings execution, analyst consensus and our composite quality grade. The list is intentionally a countdown from #7 to #1. Financial data, analyst views and company descriptions are refreshed for each monthly edition, so rankings can change as operating results, estimates and market values evolve.

▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

▌For Active Investors

Don't trade alone.

Get market intelligence delivered daily.

Get Full Access →

Not ready to subscribe? ·

▌For Active Investors

Stock research for every investor

  • Reports on any stock
  • Daily market intelligence
  • AI analyst in your pocket
  • Portfolio analysis tools
Get Full Access →

Cancel anytime

▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, free in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

▌More stock lists

More to read

All articles
7 Zero Trust Security Stocks Worth Watching in November 2026

7 Zero Trust Security Stocks Worth Watching in November 2026

This countdown spans identity, SASE, endpoint, cloud and network-security businesses across the zero trust security landscape.

Nov 18·13 min
Hims & Hers Health (HIMS): Weight-Loss Growth vs. Execution Risk
HIMS

Hims & Hers Health (HIMS): Weight-Loss Growth vs. Execution Risk

Hims & Hers Health is building a large consumer health platform, but recent growth and earnings pressure make the stock a Hold. International expansion and branded GLP-1 access could reaccelerate results, yet valuation already reflects much of the upside.

Aug 11·20 min
Top Healthcare Dividend Stocks: Our 5 Picks for November 2026

Top Healthcare Dividend Stocks: Our 5 Picks for November 2026

Healthcare dividend stocks span insurers, distributors, diagnostics, medical devices, and branded medicines in this five-stock November 2026 countdown.

Nov 18·11 min